The International Trade Commission (ITC) has ruled that Apple Watch violated AliveCor’s copyrighted technology, according to AliveCor, the world leader in FDA-cleared personal electrocardiogram (ECG) technology. Millions of counterfeit Apple Watches may no longer be sold after the ITC issued a Limited Exclusion Order (LEO), a cease and desist order, and imposed a bond of $2 per unit of infringing Apple Watches imported or sold during the Presidential review period.

The US Patent and Trademark Office’s Patent Trial and Appeal Board (“PTAB”) ruling declaring the asserted claims unpatentable has been appealed by AliveCor. The ITC has halted enforcement of its orders pending settlement of AliveCor’s appeal. The Initial Determination issued in June by Administrative Law Judge (ALJ) Cameron Elliot of the ITC was upheld by today’s decision, which is a win for AliveCor. President Biden will now conduct a 60-day review of the Final Determination.

AliveCor continues to seek redress from Apple’s anticompetitive actions in the Northern District of California in addition to challenging Apple on patent infringement in the ITC. Trial in that lawsuit is anticipated to begin in early 2024.

The ITC decision announced today is a victory for innovation and customer choice, according to Priya Abani, CEO of AliveCor. The decision emphasises how crucial it is to protect intellectual property rights for businesses like AliveCor and a plethora of others whose ideas run the risk of being stifled by a Goliath like Apple. To better the lives of individuals, we look forward to advancing and innovating our cardiac solutions.

Source: Prnewswire